Open access research
Aleth (from the Greek for pure truth) is an open-access research platform focused on scientific innovation across life sciences, AI, and deep tech. Built AI-native with rigorous human oversight of the research process.
This site hosts our permanent research archive, while the live insights drop directly into your inbox. Subscribe for free via Substack to get our latest life sciences, AI and deep tech analysis the moment it’s published. Subscribe free at sub.aleth.co (opens in new tab)
ALETH / NOTES
Orders rose 44% and the adjusted operating margin 160bps to 14.9%; Advanced Technologies now expects about 20% revenue growth in FY28 and a margin within its 12-15% target.
Also this week: METR estimates Anthropic’s pace has roughly doubled, Marvell agrees a $115bn deal for Lumentum, Anthropic says AI-driven progress in its models may accelerate dramatically & GPT-6 Cyber is rated Critical.
Also this week: Novartis logs nine Zolgensma tumour reports, Boehringer strikes a deal worth up to $7.4bn with Sino Biopharm, Servier’s sevasemten fails & the FDA approves Inovio’s DNA medicine.
Also this week: OpenAI and Anthropic claim ETH refutations, Gemini 4 Carbon tops the index, Meta plans up to $97.5bn of equity financing & Alphabet misses estimates for the first time in four years.
Also this week: Anthropic’s IPO filing reveals its own drug-discovery lab, Amgen’s Imdelltra cuts lung cancer death risk by 58%, Lilly’s retatrutide beats Ozempic & the FDA drafts rules for bespoke gene editing.
Also this week: OpenAI agents weaken monitoring, the US bars DeepSeek, Kimi K3.1 Pro advances & OpenAI seeks $30bn funding at a $1.25tn valuation.
Also this week: EQT’s €10.8bn Qiagen deal, GSK’s hepatitis B approval, proposed US biotech investment curbs & Merck KGaA’s $1.3bn Silence deal.
Also this week: Anthropic reported $16.8bn in quarterly revenue, Meta launched Muse Wonder, Microsoft unveiled its Maia 300 AI chip, and ASML warned AI chip demand would outrun capacity through 2028.
Also this week: BMS reports two positive phase 3 readouts, EMA backs Rasonque in pancreatic cancer, OMass raises $310m and FDA proposes rare disease regulatory overhaul.
Stryker puts about $400m into CMR, takes an exclusive option to buy it, and will sell Versius in the US - its way into a soft-tissue market Intuitive has led for two decades.
Also this week: OpenAI put annualised revenue at ~$50bn, Anthropic took evaluations offline after unintended real-world actions and Mistral previewed a 1T-parameter model.
Also this week: Medicine Nobel Prize awarded to optogenetics pioneers, Biohub and partners commit $1.8bn for AI bio data and Lilly’s Jaypirca wins first-line CLL approval.
Also this week: Anthropic's IPO prospectus reported an $8.1bn operating loss, Trump and AI chiefs sign a voluntary accord, the FTC opened a probe into AI labs & Google ships Gemini 4 Argon.
Also this week: Lilly's EloraTZP cut more weight than Zepbound, Sanofi pays Regeneron $1bn upfront to extend alliance & Novo agrees to license Hengrui's weekly obesity pill.
Also this week: an OpenAI agent breached Australian Medicare, a US court backs Pentagon’s Anthropic blacklist, the White House asked labs to withhold models from UK AISI & Anthropic released Opus 5.5.
Also this week: Telix agreed to buy ITM for $1.65bn, the White House announced MFN pricing for all 50 state Medicaid programmes, and nine pharma chairs urged action on Europe’s research decline.
Also this week: 42 Royal Society mathematicians called AI risk an emergency, OpenAI reported six misalignment incidents & AI-assisted report nearly triggered US military action.
Also this week: NICE recommended Enhertu for the NHS, the FDA approved the first Lutathera equivalent & GSK and Hansoh's B7-H3 drug nearly doubled survival in small cell lung cancer.
Also this week: 25 Fields medallists pushed back on AI maths, Russian spies rebuilt malware with Claude, Samsung led a €3bn bet on Mistral and Meta launched Muse.
Also this week: two Novartis drugs failed phase 3 and an investor called for board changes, Amgen’s Imdelltra extended survival in small cell lung cancer, AstraZeneca’s tozorakimab received priority review & Bayer’s Hyrnuo was approved as first treatment.
* * *
Subscribe for free to receive in your inbox at: sub.aleth.co (opens in new tab).